Steven Mah
Stock Analyst at TD Cowen
(2.79)
# 1,275
Out of 4,413 analysts
21
Total ratings
34.62%
Success rate
11.11%
Average return
Main Sectors:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $7 → $3 | $0.89 | +236.66% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $7.82 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $24.38 | +72.27% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $3.78 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $4.44 | +125.23% | 1 | Feb 22, 2023 | |
| ME 23andMe Holding Co. | Initiates: Outperform | $6 | $0.50 | +1,094.74% | 1 | Sep 22, 2022 | |
| ABSI Absci | Upgrades: Outperform | n/a | $4.74 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $2.91 | +621.65% | 2 | Jul 15, 2022 | |
| TLIS Talis Biomedical | Downgrades: Neutral | n/a | $8.62 | - | 2 | Aug 12, 2021 | |
| NTRA Natera | Maintains: Overweight | n/a | $92.88 | - | 2 | Jul 6, 2021 | |
| AKYA Akoya Biosciences | Initiates: Overweight | n/a | $3.82 | - | 1 | May 11, 2021 | |
| TWST Twist Bioscience | Initiates: Overweight | n/a | $31.23 | - | 1 | Apr 12, 2021 | |
| FLGT Fulgent Genetics | Maintains: Overweight | n/a | $20.35 | - | 1 | Mar 5, 2021 | |
| PACB Pacific Biosciences of California | Upgrades: Overweight | n/a | $1.65 | - | 1 | Feb 11, 2021 | |
| OCX OncoCyte | Upgrades: Overweight | n/a | $2.48 | - | 1 | Dec 16, 2020 | |
| ILMN Illumina | Downgrades: Neutral | n/a | $123.05 | - | 1 | Aug 7, 2020 | |
| QDEL QuidelOrtho | Maintains: Overweight | n/a | $40.55 | - | 1 | Jul 8, 2020 |
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $7 → $3
Current: $0.89
Upside: +236.66%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $7.82
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $24.38
Upside: +72.27%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $3.78
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $4.44
Upside: +125.23%
23andMe Holding Co.
Sep 22, 2022
Initiates: Outperform
Price Target: $6
Current: $0.50
Upside: +1,094.74%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $4.74
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $2.91
Upside: +621.65%
Talis Biomedical
Aug 12, 2021
Downgrades: Neutral
Price Target: n/a
Current: $8.62
Upside: -
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: n/a
Current: $92.88
Upside: -
Akoya Biosciences
May 11, 2021
Initiates: Overweight
Price Target: n/a
Current: $3.82
Upside: -
Twist Bioscience
Apr 12, 2021
Initiates: Overweight
Price Target: n/a
Current: $31.23
Upside: -
Fulgent Genetics
Mar 5, 2021
Maintains: Overweight
Price Target: n/a
Current: $20.35
Upside: -
Pacific Biosciences of California
Feb 11, 2021
Upgrades: Overweight
Price Target: n/a
Current: $1.65
Upside: -
OncoCyte
Dec 16, 2020
Upgrades: Overweight
Price Target: n/a
Current: $2.48
Upside: -
Illumina
Aug 7, 2020
Downgrades: Neutral
Price Target: n/a
Current: $123.05
Upside: -
QuidelOrtho
Jul 8, 2020
Maintains: Overweight
Price Target: n/a
Current: $40.55
Upside: -